Alzamend Neuro, Inc.ALZNNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank84
3Y CAGR+88.0%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+88.0%/yr
Quarterly compound
Percentile
P84
Within normal range
vs 3Y Ago
6.6x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 50.42% |
| Q3 2025 | -243.08% |
| Q2 2025 | 51.62% |
| Q1 2025 | 58.13% |
| Q4 2024 | -222.06% |
| Q3 2024 | 26.00% |
| Q2 2024 | 29.78% |
| Q1 2024 | -34.24% |
| Q4 2023 | 54.11% |
| Q3 2023 | -47.56% |
| Q2 2023 | -23.70% |
| Q1 2023 | 22.92% |
| Q4 2022 | 7.58% |
| Q3 2022 | -62.36% |
| Q2 2022 | 12.37% |
| Q1 2022 | 12.87% |
| Q4 2021 | -67.35% |
| Q3 2021 | 2.80% |
| Q2 2021 | -56.04% |
| Q1 2021 | -82.00% |
| Q4 2020 | -115.96% |
| Q3 2020 | -3.92% |
| Q2 2020 | 46.18% |
| Q1 2020 | 58.84% |
| Q4 2019 | 0.00% |
| Q3 2019 | -190.19% |
| Q2 2019 | 0.00% |
| Q1 2019 | -42.40% |
| Q4 2018 | 0.00% |
| Q3 2018 | 76.42% |
| Q2 2018 | 0.00% |
| Q1 2018 | -718.70% |
| Q4 2017 | 0.00% |
| Q3 2017 | 62.29% |
| Q2 2017 | 0.00% |
| Q1 2017 | 28.18% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |